EichorEICHOR
Study identifier: NCT06682975 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: Recruiting

A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants

Condition: Healthy Volunteers  ·  Sponsor: Zealand Pharma

PhasePhase 1
Planned participants124
Who can joinAll sexes, 18 Years to 45 Years
Healthy volunteersYesCheck eligibility criteria ↓
WhereLeiden, CL, Netherlands

Interested? Contact the study team ↓

For sponsors, CROs & site teams
Professional view of this study — listed sites, countries and recruiting context from the public registry. Everything below is written for patients and caregivers.See where this study is running →

About this study

The primary object in this research study is to investigate the safety and tolerability of ZP9830 in healthy study participants, and in addition, the study will investigate how ZP9830 works in the body (pharmacokinetics, PK and pharmacodynamics, PD) compared to placebo.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trial Information desk  ·  +45 88 77 36 00  ·  clinicaltrials@zealandpharma.com

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * Healthy participants. * 18-45 years of age (inclusive). * Body weight ≥50 kg. * SAD part B only: Fitzpatrick skin type I-III (Caucasian). * C-reactive protein ≤10 mg/L. * Further inclusion criteria apply. Exclusion Criteria: * Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of it might interfere with, the conduct or the interpretation of the results of the trial, or that would pose an unacceptable risk to the subject in the opinion of the Investigator \[following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature) and 12-lead ECG\]. * Any disease associated with immune system impairment, including immune mediated diseases and transplantation patients. * Any confirmed significant allergic reactions (urticaria or anaphylaxis) to insect bites. * History of neurological disorders including neuropathy, as judged by the investigator. * Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug or food (in particular any level of severity of allergy to shellfish), or multiple drug allergies (non-active hay fever is acceptable). * Further exclusion criteria apply.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (1)

Centre for Human Drug ResearchLeiden, CL, NetherlandsRecruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Leiden

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →